Dr. Lihua Qiu and Dr. Swaminathan Iyer Discuss the Latest Advances and Optimal Strategies for Peripheral T-Cell Lymphoma Treatment

Dr. Lihua Qiu and Dr. Swaminathan Iyer Discuss the Latest Advances and Optimal Strategies for Peripheral T-Cell Lymphoma Treatment

The 5th Tianjin International Lymphoma Academic Conference, serving as an academic platform to foster international academic exchange and cooperation, has actively played its role as a bridge, facilitating in-depth exchange and collaboration in the field of international lymphoma. During the conference, "Hematology Frontier" specially invited Dr. Lihua Qiu from Tianjin Medical University Cancer Institute and Hospital and Dr. Swaminathan Iyer from The University of Texas MD Anderson Cancer Center to engage in a China-International dialogue, reviewing the latest therapeutic advances in peripheral T-cell lymphoma (PTCL) and the optimization direction of treatment strategies.
STTT | Breakthrough in Kidney Cancer by Academician Xu Zhang’s Team! Neoadjuvant Regimen of Toripalimab Combined with Axitinib Assists RCC Patients with Tumor Thrombus Downstaging

STTT | Breakthrough in Kidney Cancer by Academician Xu Zhang’s Team! Neoadjuvant Regimen of Toripalimab Combined with Axitinib Assists RCC Patients with Tumor Thrombus Downstaging

Radical nephrectomy combined with venous tumor thrombus resection is the preferred treatment for renal cell carcinoma (RCC) with inferior vena cava tumor thrombus (IVC-TT) and can significantly improve patient prognosis. Preoperative neoadjuvant therapy aimed at reducing tumor thrombus level and grade is of great importance in reducing perioperative risks. Recently, the NEOTAX study, led by Academician Xu Zhang, Professor Xin Ma, and Professor Liangyou Gu from the Chinese People's Liberation Army General Hospital, was presented at the ESMO Congress (1701P). The study demonstrated that the neoadjuvant regimen of toripalimab combined with axitinib reduced tumor thrombus levels in 96.0% of RCC patients with IVC-TT and achieved thrombus downstaging in 44% of patients, thereby simplifying the surgical process. The study results were published in the Nature sub-journal Signal Transduction and Targeted Therapy (IF: 40.8). The combined treatment showed significant efficacy in reducing IVC-TT and improving surgical feasibility, offering a new direction for improving the prognosis of such patients. Below are the study details.
Dr. Jiuda Zhao Publishes Breakthrough Study in JCO, Demonstrating Electroacupuncture’s Significant Impact on Triple Antiemetic Therapy for Highly Emetogenic Chemotherapy

Dr. Jiuda Zhao Publishes Breakthrough Study in JCO, Demonstrating Electroacupuncture’s Significant Impact on Triple Antiemetic Therapy for Highly Emetogenic Chemotherapy

Recently, the team led by Dr. Jiuda Zhao at the Breast Disease Diagnosis and Treatment Center of Qinghai University Affiliated Hospital published their latest research findings in the Journal of Clinical Oncology (JCO), with an impact factor of 42.10. This study is the first to combine the current standard triple antiemetic therapy with electroacupuncture (EA) to address chemotherapy-induced nausea and vomiting (CINV) in breast cancer patients. The results demonstrate that adding EA to the standard triple antiemetic regimen significantly enhances CINV treatment outcomes. This study stands as the highest-impact acupuncture-related research publication in the field of oncology in China, showcasing the scientific prowess and innovative capabilities of Chinese scholars on the international stage. Oncology Frontier invited Dr. Jiuda Zhao to discuss this groundbreaking study.
CSCO 2024: Dr. Zhiming Li Champions New Frontiers in Lymphoma Management

CSCO 2024: Dr. Zhiming Li Champions New Frontiers in Lymphoma Management

From September 25 to September 29, the 27th National Clinical Oncology Conference and CSCO Annual Meeting, organized by the Chinese Society of Clinical Oncology (CSCO) and the Beijing Xisike Clinical Oncology Research Foundation, was successfully held in Xiamen. During the conference, Hematology Frontier invited Dr. Zhiming Li from Sun Yat-sen University Cancer Center to share his strategies for treating diffuse large B-cell lymphoma (DLBCL).
CAR-T vs. Bispecific Antibodies: Dr. Junmin Song’s Groundbreaking Myeloma Study at ESMO 2024

CAR-T vs. Bispecific Antibodies: Dr. Junmin Song’s Groundbreaking Myeloma Study at ESMO 2024

The 2024 Annual Meeting of the European Society for Medical Oncology (ESMO) was recently held in Barcelona, Spain. As one of the premier global oncology conferences, it brought together experts and scholars from around the world to share cutting-edge research and chart future directions. During the conference, Dr. Junmin Song from the Jacobi Medical Center, Albert Einstein College of Medicine, presented the first real-world study comparing BCMA CAR-T therapy with bispecific antibodies in the treatment of multiple myeloma (802MO). This presentation garnered significant attention from attendees. Hematology Frontier invited Dr. Song to provide an in-depth interpretation of the study and to discuss the future prospects of these two innovative therapies in multiple myeloma treatment.
Dr. Conconi at ESMO 2024: Charting the Course for Hematologic Malignancies Treatment

Dr. Conconi at ESMO 2024: Charting the Course for Hematologic Malignancies Treatment

The 2024 Annual Meeting of the European Society for Medical Oncology (ESMO) was recently held in Barcelona, Spain. As one of the top international conferences in the field of oncology, it gathered experts and scholars from around the world to share the latest research findings and explore future development directions. During this conference, several landmark studies in the field of hematologic malignancies were presented, providing valuable insights and references for current clinical practice and future research. Hematology Frontier invited Dr. Annarita Conconi from the University of Eastern Piedmont in Italy, one of the Chairs of the Mini Oral Session on Hematologic Malignancies, to comment on these landmark studies and to look ahead at the future trends in hematologic oncology.